Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up
Transplant International · 2024
DOI: 10.3389/ti.2024.13232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Luca Cicalese und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplant Surgery, Department of Surgery, University of Texas Medical Branch, UTMB, Galveston, TX, United States. Hauptthemen laut MEDLINE: Graft Rejection, Liver Transplantation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The diagnosis of liver antibody-mediated rejection (AMR) is challenging and likely under-recognized. The association of AMR with donor-specific antibodies (DSA), and its clinical course in relation to pathologic findings and treatment are ill defined. We identified cases of liver AMR by following the criteria outlined by the 2016 Banff Working Group. Patient demographics, native liver disease, histopathologic findings, treatment type, clinical outcome, and transaminase levels during AMR diagnosis, treatment, and resolution were determined. Patients (n = 8) with AMR average age was 55.2 years (range: 19–68). Seven of eight cases met the Banff criteria for AMR. Personalized treatment regimens consisted of optimization of immunosuppression, intravenous pulse steroids, plasmapheresis, IVIG, rituximab, and bortezomib. Five patients experienced complete resolution of AMR, return of transaminases to baseline, and decreased DSA at long-term follow-up. One patient developed chronic AMR and two patients required re-transplantation. Follow-up after AMR diagnosis ranged from one to 11 years. Because AMR can present at any time, crossmatch, early biopsy, and routine monitoring of DSA levels should be implemented following transaminase elevation to recognize AMR. Furthermore, treatment should be immediately implemented to reverse AMR and prevent graft failure, chronic damage, re-transplantation, and possibly mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Transplant Surgery, Department of Surgery, University of Texas Medical Branch, UTMB, Galveston, TX, United States.
- John Sealy School of Medicine, University of Texas Medical Branch, UTMB, Galveston, TX, United States.
- Department of Pathology, University of Texas Medical Branch, UTMB, Galveston, TX, United States.
- Department of Pathology, Cleveland Clinic, Cleveland, OH, United States.
Zitieren
APA
Cicalese, L., Walton, Z. C., Du, X., Kulkarni, R., Qiu, S., El Hag, M., & Stevenson, H. L. (2024). Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up. Transplant International. https://doi.org/10.3389/ti.2024.13232
Vancouver
Cicalese L, Walton ZC, Du X, Kulkarni R, Qiu S, El Hag M, et al. Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up. Transplant International. 2024. doi:10.3389/ti.2024.13232
BibTeX
@article{Cicalese2024,
author = {Cicalese, Luca and Walton, Zachary C and Du, Xiaotang and Kulkarni, Rupak and Qiu, Suimin and El Hag, Mohamed and Stevenson, Heather L},
title = {Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13232}
}
EUVIMED